Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



What's Going on With These Biotech Stocks?

Biotech stocks can be a lot like lottery tickets: They're worth either a whole lot or almost nothing. It's the appeal of the grand slam, the allure of striking it rich overnight, that makes them such attractive stocks.

But this risk-reward proposition also means that you have to keep a close eye on the developments at your biotechs. Like few other sectors in the investing world, news in the biotech space can make or break a company overnight. Here are some developments taking place at some biotechs that you should be watching.

Last month, Cell Therapeutics (Nasdaq: CTIC  ) was still holding out some hope that it would find success in its attempt to appeal the FDA's ruling that the company needed to run an additional clinical trial of its leading drug candidate, pixantrone. It's for use on patients with non-Hodgkin lymphoma. Fellow Fool Brian Orelli called this move a "Hail Mary" and shared his skepticism about their ability to gain approval for the drug without gathering the additional data demanded by the FDA in its original ruling.

While the FDA's agreement to re-evaluate Cell Therapeutics' new drug application on Feb. 9 held some hope for investors, the company has since voluntarily withdrawn its NDA, indicating that it needed more time to prepare for the meeting. Given that the company has already had all of the data for the clinical trials since the FDA's original ruling, it's worrisome to think about what else Cell Therapeutics thinks it needs to do to ready itself.

While pixantrone has seen some setbacks in its review process with the FDA, it has gotten a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP, to be approved by the European Commission, which is the European version of the FDA. As Brian Orelli points out, positive recommendations from the CHMP almost always result in approval by the EC.

While this likely approval has potential to let pixantrone bring in some revenue from European patients, successful sales of the drug depend on the cost-benefit decisions made by the centralized health-care systems in most European countries. When a drug's clinical trials do not produce definitive results (as was the case with pixantrone), these countries are less inclined to offer it in their medical plans.

Exelixis (Nasdaq: EXEL  ) was recently denied FDA endorsement of a quick version of phase 3 trials in order to gain approval for its prostate-cancer drug cabozantinib. However, the company has decided to push ahead with its current study without the FDA's approval in hopes of producing overwhelmingly positive data about the drug's ability to prolong survival and minimize pain in prostate cancer patients.

Earlier this week, the company also announced that it was starting a phase 1 dose-finding trial of cabozantinib in combination with abiraterone in men with metastatic castration-resistant prostate cancer. The study will try to find the maximum tolerated dose of cabozantinib in combination with abiraterone and prednisone.

Aeterna Zentaris (Nasdaq: AEZS  ) and Keryx Biopharmaceuticals (Nasdaq: KERX  ) are currently collaborating on a cancer drug called perifosine, and they expect results on phase 3 trials for perifosine's use on colon cancer patients in the next few weeks. Perifosine is also in phase 3 of its trials for use on a type of blood cancer called multiple myeloma. The stocks of Aeterna and Keryx responded very favorably -- up 22% and 33%, respectively -- on Monday, following a blog article that touted the drug's unappreciated potential. Neither company released news that could have moved the stock, while others have called into question the original author's credibility. Both companies shed a large portion of those gains in the following trading sessions.

While failing its phase 3 trials would be a bad sign for its success in treating multiple myeloma, there are many cases of drugs working on one type of cancer but not another. For example, Bayer and Onyx Pharmaceuticals collaborated on a drug called Nexavar, which failed to work on lung cancer but works on liver and kidney cancers. Also, Pfizer has a drug called Sutent, which does not work on breast, prostate, lung, or liver cancer, but works on kidney cancers and a few others.

With high-risk propositions on sometimes unproven drugs, biotech investing is not for everyone. And that's OK. If you'd like to invest in lower-risk companies with more certainty of success, check out our special free report: "3 American Companies Set to Dominate the World." It's available free for a limited time. Just click here to get your copy.

Jim Royal, Ph.D. does not own shares of any of the companies mentioned. The Motley Fool owns shares of Exelixis. Motley Fool newsletter services have recommended buying shares of Exelixis and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (3) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 08, 2012, at 4:09 PM, OBAMABB wrote:

    WOW! 3 Trials for Pixantrone Proving it works and you say inconclusive? are you PAZDUR The FDA Thief?

    Amazing How short are you and your Buddies In this stock Maybe 25 Million?

    Lets see is that 20 or 25 times you have Bashed CTIC's Pixantrone!

    EMA Recommendation and you think the drug does not work?

    Do you comprehend anything?

    Or do you just to ignore the facts as long as you fools can steal and get rich shorting the stock?

    Pixantrone was proven to have a 65% 2 years survival rate! all other resulting Chemo agents a couple of months at best!

    A 24% C/R over DOX and all currently available Chemo drugs!

    Pixantrone Has a 3 year 92% S/R (CHOP) All the other patients Died with in 3-6 months And you say the drug does not work?

    You Better prey you never need Pixantrone!

    What A Basher Rag!

    Stop the Lies!

  • Report this Comment On March 08, 2012, at 4:13 PM, OBAMABB wrote:

    This is only one of three trials but all 3 trials show the same results Pixantrone works Period!

    Twenty-eight of 29 enrolled patients received at least 1 cycle of FPD-R (median, 5 cycles). Pixantrone 120 mg/m(2) was identified as the recommended dose in this regimen. Grade 3-4 adverse events were primarily hematologic; grade 3-4 lymphopenia occurred in 89% of patients and leukopenia in 79%. No patients developed congestive heart failure or grade 3-4 cardiac adverse events. Left ventricular ejection fraction decreases occurred in 8 (29%) patients, and most were grade 1 or 2, transient, and asymptomatic. The overall response rate was 89%. Estimated survival was 96% after 1 year and 92% after 3 years.


    The FPD-R regimen was well-tolerated and highly active in patients with relapsed or refractory indolent NHL. Cancer 2011;. © 2011 American Cancer Society.

    Copyright © 2011 American Cancer Society.

    It just shows that they just don't want you to see the truth!

  • Report this Comment On March 08, 2012, at 4:55 PM, futurewalk wrote:

    I agree with the above comment. The constant bashing of CTIC has been unseemly and at odds with the facts of the story as they've evolved.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1805014, ~/Articles/ArticleHandler.aspx, 10/23/2016 4:37:09 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
AEZS $4.94 Up +0.05 +1.02%
Aeterna Zentaris CAPS Rating: *****
CTIC $0.40 Down -0.01 -1.44%
CTI BioPharma CAPS Rating: **
EXEL $11.56 Down -0.18 -1.53%
Exelixis CAPS Rating: ****
KERX $4.69 Up +0.05 +1.08%
Keryx Biopharmaceu… CAPS Rating: **